公开(公告)号：US20240293439A1

公开(公告)日：2024-09-05

申请号：US18374500

申请日：2023-09-28

申请人： NuCana plc

发明人： Hugh Griffith

IPC分类号： A61K31/7068 ,  A61K9/00 ,  A61P35/00 ,  G01N33/50 ,  G01N33/574

CPC分类号： A61K31/7068 ,  A61P35/00 ,  G01N33/5011 ,  G01N33/57496 ,  A61K9/0019 ,  G01N2333/90206 ,  G01N2800/52

摘要： The invention relates to 5-fluoro-2′-deoxyuridine-5′-O-[1-naphthyl (benzoxy-L-alaninyl)] phosphate (NUC-3373), or a pharmaceutically acceptable salt thereof, for use in the treatment of cancer, in particular by intravenous infusion for a continuous period of up to 10 hours. The invention also relates to methods of treating cancer by administration of NUC-3373 to particular sub-groups of cancer patient. The invention further relates to methods for selecting a patient for treatment with NUC-3373.

公开(公告)号：US12042530B2

公开(公告)日：2024-07-23

申请号：US17170044

申请日：2021-02-08

申请人： University of Virginia Patent Foundation ,  The University of Birmingham

发明人： Donald F. Hunt ,  Jeffrey Shabanowitz ,  Stacy Alyse Malaker ,  Victor H. Engelhard ,  Angela L. Ambakhutwala ,  Kara L. Cummings ,  Rebecca C. Obeng ,  Mark Cobbold

IPC分类号： A61K38/00 ,  A61K35/15 ,  A61K35/17 ,  A61K39/00 ,  A61K45/06 ,  C07K16/28 ,  G01N33/574 ,  G01N33/68

CPC分类号： A61K39/0011 ,  A61K35/15 ,  A61K35/17 ,  A61K39/001106 ,  A61K39/00111 ,  A61K39/001113 ,  A61K39/001132 ,  A61K39/001151 ,  A61K39/001156 ,  A61K39/001157 ,  A61K39/001162 ,  A61K39/001164 ,  A61K39/001166 ,  A61K39/001181 ,  A61K39/001182 ,  A61K39/001184 ,  A61K39/001186 ,  A61K39/001188 ,  A61K39/001189 ,  A61K39/00119 ,  A61K39/001192 ,  A61K39/001193 ,  A61K39/001194 ,  A61K39/001195 ,  A61K39/001197 ,  A61K45/06 ,  C07K16/2809 ,  C07K16/2833 ,  G01N33/57496 ,  G01N33/6863 ,  A61K2039/5154 ,  A61K2039/5158 ,  A61K2039/55516 ,  A61K2039/57 ,  C07K2317/31

摘要： A set of target peptides are presented by HLA A*0101, A*0201, A*0301, B*4402, B*2705, B*1402, and B*0702 on the surface of disease cells. They are envisioned to among other things (a) stimulate an immune response to the proliferative disease, e.g., cancer, (b) to function as immunotherapeutics in adoptive T cell therapy or as a vaccine, (c) facilitate antibody recognition of tumor boundaries in surgical pathology samples, (d) act as biomarkers for early detection and/or diagnosis of the disease, and (e) act as targets in the generation antibody-like molecules which recognize the target-peptide/MHC complex.

公开(公告)号：US20240018484A1

公开(公告)日：2024-01-18

申请号：US18452952

申请日：2023-08-21

申请人： NATIONAL TAIWAN UNIVERSITY

发明人： Pan-Chyr Yang ,  Huei-Wen Chen ,  Wan-Jiun Chen

IPC分类号： C12N5/095 ,  C12N5/09 ,  G01N33/50 ,  G01N33/574

CPC分类号： C12N5/0695 ,  C12N5/0693 ,  G01N33/5017 ,  G01N33/574 ,  G01N33/5011 ,  G01N33/57492 ,  G01N33/57496 ,  C12N2502/30 ,  C12N2501/605 ,  G01N2800/52 ,  G01N2333/4706 ,  G01N2333/475 ,  G01N2333/4753 ,  G01N2333/52 ,  G01N2333/71 ,  G01N2333/715 ,  G01N2333/7158

摘要： An in vitro co-culture system comprising cancer-associated fibroblasts (CAFs) and cancer cells for producing and maintaining cancer stem cells and uses thereof for identifying agents capable of reducing cancer cell stemness. Also disclosed herein are a paracrine network through which CAFs facilitate production and/or maintenance of cancer stem cells and the use of components of such a paracrine network for prognosis purposes and for identifying cancer patients who are likely to respond to certain treatment.

公开(公告)号：US20230417753A1

公开(公告)日：2023-12-28

申请号：US18036500

申请日：2021-11-18

申请人： UNIVERSITÉ PARIS CITÉ ,  INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE ,  CLINI HOLDING ,  INSTITUT CURIE

发明人： Véronique BAUD ,  Baptiste ELUARD

IPC分类号： G01N33/574

CPC分类号： G01N33/57415 ,  G01N33/57496 ,  G01N2440/14

摘要： An in vitro method belonging to the field of medicine, more specifically the field of cancer prognostic and therapeutic management, is disclosed. The method is for classifying a subject afflicted with a solid cancer as having a good prognosis or a poor prognosis. The method comprises detecting in a cancer cell sample from the subject phosphorylated RelB protein at the serine residue 472 and/or detecting a RelB homolog phosphorylated at a corresponding serine. A kit for implementing the method also is disclosed.

公开(公告)号：US11813305B2

公开(公告)日：2023-11-14

申请号：US17157126

申请日：2021-01-25

申请人： IMMUNE SYSTEM KEY LTD.

发明人： Yoram Devary ,  Uziel Sandler

IPC分类号： A61K38/10 ,  A61K31/337 ,  A61K31/704 ,  A61K45/06 ,  A61P35/00 ,  G01N33/53 ,  C12Q1/6886 ,  G01N33/574 ,  A61K38/17 ,  A61K39/395

CPC分类号： A61K38/10 ,  A61K31/337 ,  A61K31/704 ,  A61K38/1709 ,  A61K39/39558 ,  A61K45/06 ,  A61P35/00 ,  C12Q1/6886 ,  G01N33/53 ,  G01N33/574 ,  G01N33/57496 ,  C12Q2600/106 ,  C12Q2600/158 ,  G01N2800/52 ,  A61K31/337 ,  A61K2300/00 ,  A61K38/1709 ,  A61K2300/00

摘要： Provided are methods, agents and kits for use in assessing the effect of treatment on cancer patients. Further provided is a combination therapy for reducing the administered standard of care doses of anti-cancer agents in treated cancer patients.

公开(公告)号：US11768137B2

公开(公告)日：2023-09-26

申请号：US16571785

申请日：2019-09-16

申请人： VENTANA MEDICAL SYSTEMS, INC.

发明人： Nelson Alexander ,  Aoune Barhoumi ,  Lisa Gallegos ,  Stacey Stanislaw

IPC分类号： G01N1/40 ,  B01L3/00 ,  C12Q1/6886 ,  G01N1/28 ,  G01N33/574

CPC分类号： G01N1/4077 ,  B01L3/502753 ,  B01L3/502761 ,  C12Q1/6886 ,  G01N1/286 ,  G01N33/57496 ,  B01L2200/0652 ,  B01L2300/0681 ,  B01L2400/0403 ,  B01L2400/086 ,  G01N2001/2866 ,  G01N2001/4088

摘要： The present disclosure provides a method of separating cellular particles from a tissue sample and then sorting the cellular particles into two or more cellular particle populations.

公开(公告)号：US11747339B2

公开(公告)日：2023-09-05

申请号：US16949252

申请日：2020-10-21

申请人： Ventana Medical Systems, Inc.

发明人： Fernando Jose Rebelo do Couto ,  Zhiming Liao ,  Andrea Muranyi ,  Kandavel Shanmugam ,  Shalini Singh ,  Yifei Zhu

IPC分类号： C07K16/00 ,  G01N33/574 ,  C07K16/22 ,  C07K16/30

CPC分类号： G01N33/57496 ,  C07K16/22 ,  C07K16/30 ,  C07K2317/20 ,  C07K2317/34 ,  C07K2317/92 ,  G01N2333/485

摘要： The invention provides anti-human pro-epiregulin and anti-human amphiregulin antibodies and methods of using the same. Anti-EREG antibodies raised against amino acids 148-169 and 156-169 of the human EREG protein, and anti-AREG antibodies raised against amino acids 238-252 of the human AREG protein are disclosed. Methods of using these antibodies to detect EREG and AREG and kits and other products for performing such methods are also disclosed.

公开(公告)号：US20230272055A1

公开(公告)日：2023-08-31

申请号：US18062924

申请日：2022-12-07

申请人： Incyte Corporation

发明人： Patrick Mayes ,  Horacio G. Nastri ,  Rebecca A. Buonpane ,  Edimara S. Reis ,  Shaun M. Stewart ,  Jing Zhou ,  Marc C. Deller ,  Hsiang-Ting Lei ,  Leslie Brooke Epling McQuirter ,  Yonghong Zhao ,  Hamza Celik ,  Brittney Melissa Wass

IPC分类号： C07K16/18 ,  A61P35/00 ,  A61K31/519 ,  A61K39/395 ,  G01N33/574

CPC分类号： C07K16/18 ,  A61P35/00 ,  A61K31/519 ,  A61K39/3955 ,  G01N33/57496 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2317/73 ,  A61K2039/505

摘要： Anti-mutant calreticulin (mutCALR) antibodies are disclosed. Also disclosed are related nucleic acids, vectors, cells, kits, and pharmaceutical compositions. Methods of treating or diagnosing myeloproliferative neoplasms with the anti-mutCALR antibodies are also disclosed.

公开(公告)号：US20230258646A1

公开(公告)日：2023-08-17

申请号：US18131559

申请日：2023-04-06

申请人： ALBERT EINSTEIN COLLEGE OF MEDICINE

发明人： Harry OSTRER ,  Johnny C. LOKE ,  Alexander PEARLMAN

IPC分类号： G01N33/574 ,  C12Q1/6886

CPC分类号： G01N33/57496 ,  C12Q1/6886 ,  G01N33/57484 ,  G01N33/57415 ,  G01N33/57449 ,  C12Q2600/156 ,  G01N2333/4748 ,  G01N2440/14 ,  G01N2800/50 ,  G01N2333/4703 ,  G01N2333/9108

摘要： Heritable mutations in the BRCA1 and BRCA2 and other genes in the DNA double-strand break (DSB) repair pathway increase risk of breast, ovarian and other cancers. In response to DNA breaks, the proteins encoded by these genes bind to each other and are transported into the nucleus to form nuclear foci and initiate homologous recombination. Flow cytometry-based functional variant analyses (FVAs) were developed to determine whether variants in BRCA1 or other DSB repair genes disrupted the binding of BRCA1 to its protein partners, the phosphorylation of p53 or the transport of the BRCA1complex to the nucleus in response to DNA damage. Each of these assays distinguished high-risk BRCA1 mutations from low-risk BRCA1 controls. Mutations in other DSB repair pathway genes produced molecular phenocopies with these assays. FVA assays may represent an adjunct to sequencing for categorizing VUS or may represent a stand-alone measure for assessing breast cancer risk.

公开(公告)号：US11719696B2

公开(公告)日：2023-08-08

申请号：US17067728

申请日：2020-10-11

申请人： The University of Vermont and State Agricultural College

发明人： Christopher Francklyn ,  Karen M. Lounsbury ,  Tamara Williams

IPC分类号： G01N33/573 ,  C12Q1/25 ,  C12Q1/6883 ,  C12Q1/6886 ,  G01N33/574

CPC分类号： G01N33/573 ,  C12Q1/25 ,  C12Q1/6883 ,  C12Q1/6886 ,  G01N33/57496 ,  C12Q2600/118 ,  C12Q2600/158 ,  G01N2333/9015 ,  G01N2800/52 ,  G01N2800/7014

摘要： The invention includes, in part, methods and compounds for diagnosing diseases and conditions characterized by altered threonyl-tRNA synthetase (TARS) activity, which include, but are not limited to diseases and conditions in which angiogenesis is altered. In some embodiments of the invention, a level of a TARS molecule is determined and compared to a control level of TARS to assess onset, progression, and/or regression of a disease or condition associated with altered TARS activity.